Pharmaceutical Investing Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
